All-cause mortality before and after DAA availability among people living with HIV and HCV: An international comparison between 2010 and 2019.
Requena MB, Protopopescu C, Stewart AC, van Santen DK, Klein MB, Jarrin I, Berenguer J, Wittkop L, Salmon D, Rauch A, Prins M, van der Valk M, Sacks-Davis R, Hellard ME, Carrieri P, Lacombe K; on behalf of the InCHEHC Collaboration
HIV + AIDS Hepatitis C Global Infectious Disease Threats
Risk of primary incident hepatitis C infection following bacterial sexually transmissible infections among gay and bisexual men in Australia from 2016 to 2020.
Harney BL, Sacks-Davis R, Agius P, van Santen DK, Traeger MW, Wilkinson AL, Asselin J, Fairley CK, Roth N, Bloch M, Matthews GV, Donovan B, Guy R, Stoové M, Hellard ME, Doyle JS
Hepatitis C Global Infectious Disease Threats
A Diversity Covering (DiCo) Plasmodium vivax apical membrane antigen-1 vaccine adjuvanted with RFASE/RSL10 yields high levels of growth-inhibitory antibodies.
Faber BW, Yeoh LM, Kurtovic L, Mol WEM, Poelert M, Smits E, Rodriguez Garcia R, Mandalawi-Van der Eijk M, van der Werff N, Voorberg-van der Wel A, Remarque EJ, Beeson JG, Kocken CHM.
Malaria
Characteristics of attrition within the SuperMIX cohort of people who inject drugs: A multiple event discrete-time survival analysis.
Abdelsalam S, Agius PA, Sacks-Davis R, Roxburgh A, Livingston M, Maher L, Hickman M, Dietze P
Injecting Drug Use
Using serological diagnostics to characterize remaining high-incidence pockets of malaria in forest-fringe Cambodia.
Grimée M, Tacoli C, Sandfort M, Obadia T, Taylor AR, Vantaux A, Robinson LJ, Lek D, Longley RJ, Mueller I, Popovici J, White MT, Witkowski B
Malaria
WHO hepatitis C elimination targets: the global equity challenge.
Heath K, Hill A
Hepatitis C Global Infectious Disease Threats